Search Results
You are looking at 1 - 1 of 1 items for
- Author: Lin Xie x
- Refine by access: All content x
Search for other papers by Shou-Si Lu in
Google Scholar
PubMed
Search for other papers by Yun-Li Yu in
Google Scholar
PubMed
Search for other papers by Hao-Jie Zhu in
Google Scholar
PubMed
Search for other papers by Xiao-Dong Liu in
Google Scholar
PubMed
Search for other papers by Li Liu in
Google Scholar
PubMed
Search for other papers by Yao-Wu Liu in
Google Scholar
PubMed
Search for other papers by Ping Wang in
Google Scholar
PubMed
Search for other papers by Lin Xie in
Google Scholar
PubMed
Search for other papers by Guang-Ji Wang in
Google Scholar
PubMed
Berberine (BBR), a hypoglycemic agent, has shown beneficial metabolic effects for anti-diabetes, but its precise mechanism was unclear. Glucagon-like peptide-1 (GLP-1) is considered to be an important incretin that can decrease hyperglycemia in the gastrointestinal tract after meals. The aim of this study was to investigate whether BBR exerts its anti-diabetic effects via modulating GCG secretion. Diabetes-like rats induced by streptozotocin received BBR (120 mg/kg per day, i.g) for 5 weeks. Two hours following the last dose, the rats were anaesthetized and received 2.5 g/kg glucose by gavage. At 15-minute and 30-minute after glucose load, blood samples, pancreas, and intestines were obtained to measure insulin and GCG using ELISA kit. The number of L cells in the ileum and β-cells in the pancreas were identified using immunohistology. The expression of proglucagon mRNA in the ileum was measured by RT-PCR. The results indicated that BBR treatment significantly increased GCG levels in plasma and intestine (P<0.05) accompanied with the increase of proglucagon mRNA expression and the number of L-cell compared with the controls (P<0.05). Furthermore, BBR increased insulin levels in plasma and pancreas as well as β-cell number in pancreas. The data support the hypothesis that the anti-diabetic effects of BBR may partly result from enhancing GCG secretion.
